Perrigo Company plc

source: coverage-next-full ticker: PRGO step: "01" title: Business Overview — Perrigo Company plc created: 2026-05-29

Step 01 — Business Overview

Company at a Glance

Perrigo Company plc is the world's largest manufacturer of over-the-counter (OTC) store-brand (private-label) consumer healthcare products. Headquartered in Dublin, Ireland, and listed on the NYSE, Perrigo operates as the hidden engine behind the store-brand OTC medicine shelves at Walmart, CVS, Walgreens, Target, Costco, Kroger, and Amazon. When a consumer reaches for the CVS-brand ibuprofen instead of Advil, there is a high probability it was manufactured by Perrigo.

The company pivoted decisively in 2021 by divesting its Rx pharmaceutical generics business to become a pure-play consumer self-care company. The subsequent acquisition of HRA Pharma in 2022 added a branded international OTC portfolio — shifting the mix toward branded products in Europe while maintaining the dominant private-label position in the Americas.

What Perrigo Does

Perrigo's core value proposition is straightforward: it develops, manufactures, and distributes store-brand equivalents of branded OTC products at materially lower prices, giving retailers high-margin, lower-cost alternatives to national brands. This "value brand" model benefits retailers (higher private-label margins vs. branded resale) and consumers (20–30% savings on therapeutically equivalent products).

Secondary value: In international markets (primarily Europe), Perrigo owns branded OTC products — not private-label — that compete directly with Haleon, Kenvue, and Reckitt product lines.

Business Segments

Consumer Self-Care Americas (CSCA) — ~55–67% of Revenue

The flagship segment. CSCA is the largest private-label OTC manufacturer in the United States. It manufactures and distributes store-brand equivalents across categories:

Opill® (norgestrel 0.075mg) is noteworthy: the first-ever FDA-approved daily oral contraceptive available OTC without a prescription. Approved July 2023, launched early 2024. Perrigo holds the exclusive OTC right, representing a rare branded growth vector within CSCA.

Infant Formula (~$360M revenue, ~8–9% of total): Perrigo is the largest US private-label infant formula manufacturer (a market segment not supplied by Abbott or Mead Johnson). The 2022 Abbott recall created a temporary windfall. A strategic review was announced in November 2025 to evaluate divestiture or other options.

Consumer Self-Care International (CSCI) — ~33–45% of Revenue

A branded OTC portfolio in Europe and Australia, significantly enlarged by the HRA Pharma acquisition. Key brands:

HRA Pharma also brought a pipeline of Rx-to-OTC switch projects — a strategic growth avenue for branded consumer health across Europe.

Transformation Story (2021–2026)

Perrigo's recent history is defined by two decisions of opposing nature:

Rx Divestiture (2021): Sold the prescription generics business, refocusing on consumer OTC. This simplified the business and reduced generic pharma pricing/volume risk. It also generated cash, temporarily improving the balance sheet.

HRA Pharma Acquisition (2022): Paid ~€1.8B for HRA Pharma, funded predominantly with debt. This added branded European OTC and reproductive health products (ellaOne, Plan B) but substantially levered the balance sheet (net leverage jumped to ~5x). Post-acquisition integration has been the dominant strategic focus since.

The net result: Perrigo is now a mid-complexity consumer health company with a leading private-label US franchise, a branded European portfolio, and a leveraged balance sheet in need of repair.

Key Facts

source: coverage-next-full ticker: PRGO step: "04" title: Financial Snapshot — 3-Year P&L Summary created: 2026-05-29

Step 04 — Financial Snapshot

Annual P&L Summary (USD millions)

Key Note on GAAP vs. Adjusted: Perrigo's GAAP financials are persistently negative due to (1) non-cash amortization of acquired intangibles from HRA Pharma and other M&A, and (2) recurring restructuring/impairment charges. The FY2025 GAAP net loss of -$1,425M was driven primarily by ~$1.3B+ in non-cash goodwill and intangible impairments (Q4 2025 and Q1 2026 charges) tied to the CSCI portfolio revaluation following the Dermacosmetics divestiture announcement and weaker-than-expected performance. Management and analysts focus on adjusted EPS (excluding amortization, impairments, restructuring) for normalized earnings power. Adjusted EPS of ~$2.50 in FY2025 vs. GAAP EPS of -$10.29 illustrates the magnitude of these adjustments.

Revenue Trend Analysis

Revenue grew from $4,139M in FY2021 to a peak of $4,656M in FY2023 (+12.5% over 2 years), benefiting from:

• HRA Pharma consolidation (added ~$500–600M of CSCI revenue from mid-2022)
• Abbott infant formula recall market share gains (2022)
• Post-COVID cough/cold volume recovery

The subsequent decline to $4,373M (FY2024) and $4,253M (FY2025) reflects:

• CSCA softness: competitive pricing pressure and infant formula volume normalization
• CSCI headwinds: unfavorable currency, Dermacosmetics under review
• Absence of 2022's non-repeating infant formula windfall

FY2026 consensus: ~$4,140M (-2.7% further decline), as divestitures partially offset Opill ramp and Project Energize cost savings.

Gross Margin Analysis

Gross margin collapsed to 32.7% in FY2022 (HRA integration costs, supply chain inflation, working capital build) then recovered to 36.1% in FY2023. FY2024–FY2025 stabilization at ~35% represents the new normalized level. Management targets 22–24% adjusted EBIT margin (implying incremental operating leverage above the current ~35% gross margin level). Adjusted EBIT margin in FY2024 was roughly 10–11%, leaving a gap vs. target.

Cost Structure

The dominant intangible amortization burden (~$250–350M/year) is the primary driver of the GAAP vs. adjusted divergence.

Interest Expense

With ~$3.6B in total debt, interest expense is substantial:

• FY2024: ~$210–230M (estimated at ~5.5–6% blended rate on mix of fixed senior notes and floating revolver)
• FY2025: similar level — ~$200–225M

Interest expense effectively absorbs approximately half of adjusted EBITDA (~$450M), leaving FCF generation thin relative to debt level.

Adjusted EBITDA Trend

Management is targeting a path to 22–24% adjusted EBIT margin, roughly double the FY2024–FY2025 level, through Project Energize ($140–170M gross savings by end-2026) and portfolio optimization.

EPS Bridge (GAAP to Adjusted)

Starting from GAAP EPS of -$1.25 (FY2024):

• Add back: ~$250–300M amortization of acquisition-related intangibles
• Add back: ~$50–100M restructuring/impairment charges
• Add back: ~$30–50M non-cash share-based comp and other items
• Tax impact on adjustments
• Approximate adjusted EPS ≈ $2.50–2.70

This bridge is essential for evaluating whether the business is generating real economic returns. The ~$280M+ in annual amortization from HRA is a non-cash charge that distorts GAAP earnings for 10–15 years post-acquisition.

Three-Year P&L Scorecard

source: coverage-next-full ticker: PRGO step: "12" title: Catalysts — Near-Term Drivers & Bull/Bear Cases created: 2026-05-29

Step 12 — Catalysts

Catalyst Timeline (2026–2027)

Near-Term Catalysts (12 Months)

1. Dermacosmetics Divestiture Completion (~$350M)

Status: Proposed sale announced July 2025; expected close H1 2026 (subject to regulatory approval) Impact: Proceeds designated for debt reduction

• Best case: €327M (~$350M) received; net debt falls from ~$3.1B to ~$2.75B; leverage ratio improves ~0.4–0.5x
• This is the largest near-term debt reduction catalyst and has the highest probability of occurring (management-controlled)

2. Infant Formula Strategic Review Outcome

Status: Announced November 2025; review ongoing; conclusion expected mid-2026 Impact: ~$360M revenue (~8–9% of total) at below-average margins

• Best case: Sale at 1.0–1.5x revenue (~$360–540M) significantly reduces leverage
• Base case: Sale at ~0.8–1.0x revenue; modest proceeds but removes a low-quality revenue stream
• Bear case: No qualified buyer; business retained; drag continues; strategic review overhang lingers

3. Project Energize Savings Realization

Target: $140–170M gross annualized savings by end of FY2026 ($80–130M net) Impact: First full-year benefit appears in FY2026 adj. EBITDA

• If ~$100M net savings flow through in FY2026: adj. EBITDA could reach $530–540M vs. ~$440M in FY2024
• This improvement would flow directly into FCF and reduce leverage ratio by ~0.3–0.4x organically
• Highest-probability positive catalyst — management has been specific and credible about this program

4. Opill Revenue Ramp

Status: Launched OTC in early 2024; building distribution and awareness through 2025–2026 Impact: Modest near-term but meaningful optionality

• FY2026 Opill revenue estimate: $50–100M+ (immature; limited analyst consensus)
• Long-term: If oral contraceptive OTC market reaches $500M+ revenue category, Opill could become $200–400M business with strong margins
• Visibility-creating events: quarterly disclosure of new product revenue, distribution milestones

5. Q2/Q3 2026 Earnings Inflection

Following Dermacosmetics divestiture close + Project Energize savings + Opill ramp:

• First quarter showing YoY adj. EBITDA margin expansion would be a sentiment catalyst
• Market re-pricing from "distressed value" to "restructuring success" could compress discount multiple
• Key metric: Does adj. EPS guidance midpoint rise above $2.40 (current consensus high-end)?

Negative Catalysts to Monitor

1. Dividend cut announcement: A dividend cut, while ultimately credit-positive, would be a stock price negative short-term and signal FCF stress
2. Covenant breach or refinancing complications: Any signal of lender stress would be severely negative
3. FDA Warning Letter at major facility: Immediate operational and financial impact; share price collapse risk
4. Infant formula review fails to find buyer: Retained drag + capital tied up in low-return asset
5. CSCA pricing further compressed by retailer consolidation: Margin miss triggers leverage concern spiral

Bull Case

• Project Energize delivers $100–130M net savings by end-FY2026, Dermacosmetics proceeds ~$350M reduce leverage to ~4x, and Opill emerges as a $150M+ revenue category-creating product; the combined effect drives adj. EBITDA from ~$440M toward $580–600M by FY2027, leverage hits <3x ahead of schedule, and the market re-rates from 8x to 12x adj. EBITDA, implying equity value of $15–22/share.
• Infant formula sale at 1.2x revenue ($430M) provides a second major debt paydown catalyst in H2 2026, accelerating the deleveraging timeline and potentially funding a dividend cut-to-reinvest or a credit upgrade.
• Consumer trade-down tailwind from persistent inflation drives CSCA private-label market share gains, inflecting organic revenue from -3% to +2%, while the 10% dividend yield attracts income investors and provides a valuation floor.

Bear Case

• Project Energize savings are offset by ongoing CSCA pricing concessions and input cost re-inflation, leaving adj. EBITDA stuck at $400–420M and leverage structurally above 4x; lenders add covenant restrictions that limit operational flexibility.
• The infant formula strategic review fails to find a buyer at acceptable terms, and the Dermacosmetics sale closes at a significant discount to the €327M ask, delivering <$200M in net proceeds; the combination leaves leverage elevated and raises dividend sustainability questions that management eventually cannot avoid.
• Opill faces unexpectedly slow consumer adoption (awareness, access, cost barriers) and becomes a rounding-error revenue contributor, while a new competitor pursues FDA approval for an OTC contraceptive, eliminating Perrigo's first-mover premium; PRGO stock tests new 52-week lows below $9 on leverage + growth fears.